DAIRY: Infant formula suppliers A2 Milk and Wattle Health Australia have strengthened their regulatory position in the lucrative Chinese market.
A2 Milk’s application to continue selling its infant formula products has been approved by Beijing’s health regulator, the China Food and Drug Administration.
Formula manufacturer Synlait Milk, which has been in partnership with A2 Milk since 2010, submitted the mandatory CFDA application in May. All infant formula manufacturers must register brands and recipes with the CFDA for products to be imported into China from January 1.
Also, foreign manufacturers of infant formula products in China must register the canning facility used to blend and pack the products with the Certification and Accreditation Administration of People’s Republic of China (CNCA).
From January 1, all infant formula to be sold in China must be manufactured by a facility accredited by the CNCA, and each facility can only register up to three brands.
A2 Milk’s CFDA registration included tests on raw materials and finished products, certification of manufacturing standards, formulation assessment and packaging.
Chief executive Geoff Babidge said the company’s multichannel infant formula strategy in Chinese and English-labelled products ha positioned A2 Milk well in the context of regulatory requirements. “We look forward to the continued expansion of our business in China”, he said.
Wattle Health has completed its $5m acquisition of 5 per cent interest in Australian infant formula maker Blend & Pack, which is licensed by the CNCA to produce infant formula for China’s market.
As seen in The Australian, September 29th 2017.